Skip to main content
. 2018 May 18;9:349. doi: 10.3389/fneur.2018.00349

Figure 1.

Figure 1

Small molecule compounds alleviating myotonic dystrophy type 1 (DM1) pathogenesis. Small molecule compounds which mitigated DM1 pathogenesis in different experimental systems are shown. The molecules are classified into a few categories depending on their presumable mechanisms of action. All the molecules are believed to act independently of direct interactions with expanded CUG repeats RNA.